Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
*ST Jingfeng involved in two major lawsuits with a total amount involved of nearly 29 million yuan
Log in to the Sina Finance App, and search for 【Information Disclosure】 to view more assessment grades
Hunan Jingfeng Pharmaceutical Co., Ltd. (stock abbreviation: *ST Jingfeng, stock code: 000908) issued an announcement on March 26, disclosing two major litigation matters involving the company and its subsidiaries. Of these, in one case, a court of first instance has already rendered a judgment; the company’s subsidiary, as the plaintiff, was awarded approximately 10.3881 million yuan. In the other case, the court has accepted the filing; the company, as the defendant, is facing claims of approximately 18.3382 million yuan. The total amount involved in the two cases is approximately 28.7263 million yuan.
The announcement shows that Case One is a dispute between the company’s subsidiary, Shanghai Jingfeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Shanghai Jingfeng”), and Shanghai Baoji Pharmaceutical Co., Ltd. (hereinafter referred to as “Baoji Pharmaceutical”) concerning the return of property and compensation for property loss. The People’s Court of Baoshan District of Shanghai has issued a first-instance judgment for this case, ordering Baoji Pharmaceutical to compensate Shanghai Jingfeng for equipment losses totaling 57 items for an aggregate amount of 10.2385 million yuan. The judgment has not yet become effective. Baoji Pharmaceutical may file an appeal within fifteen days from the date the judgment is served. The case amount for Case One also includes the case acceptance fees of 0.0646 million yuan and appraisal fees of 0.0850 million yuan that Shanghai Jingfeng is responsible for, totaling approximately 10.3881 million yuan.
Case Two is a decoration and renovation contract dispute, in which Suzhou Shenmei Design and Construction Co., Ltd. (hereinafter referred to as “Shenmei Design”) sues Shanghai Jingfeng and _ST Jingfeng. The People’s Court of Wuzhong District, Suzhou has accepted the case; it has not yet been scheduled for trial. Shenmei Design requests the court to order Shanghai Jingfeng to pay renovation fees of 8.5 million yuan, a liquidated damages amount of 2.4260 million yuan, overdue payment interest of 5.8822 million yuan (temporarily calculated through November 9, 2025), and legal fees of 1.53 million yuan, for a total of approximately 18.3382 million yuan. Shenmei Design also requires _ST Jingfeng to bear joint and several liability for the repayment as the sole shareholder of Shanghai Jingfeng.
*ST Jingfeng states that for Case One, although there is already a first-instance judgment, it has not yet become effective, and the specific impact on the company’s current-period profits or future-period profits remains uncertain. For Case Two, since it has not yet been scheduled for trial, the impact on the company’s profits cannot be predicted. The final accounting treatment and the impact amount will be based on the results confirmed by the accounting firm after auditing. The company will closely monitor the subsequent progress of the above cases and promptly fulfill its information disclosure obligations.
Click to view the full text of the announcement>>
Statement: The market involves risks; investment should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are any discrepancies, please refer to the actual announcement. If you have questions, please contact biz@staff.sina.com.cn.
A wealth of information and precise analysis—right on the Sina Finance App
Editor: Xiao Lang Express